“We are primed to execute across an expansive phase three program of 3944 targeting potential approval starting in 2028.”

In context

“. We continue to advance our potentially first-in-class oral Gipper antagonist that is in phase two, and additional phase one studies of agents with diverse modalities and mechanisms. These include an injectable ultra-long-acting GiPA agonist, a potential quarterly dose injectable GLP-1 receptor agonist, and oral candidates. To summarize, today's results are clear. Vespa three achieved its two main objectives, reinforcing 3944's potential potent and tolerable monthly profile. The ultra-long-acting GLP-1 receptor agonist serves as a foundation for our differentiated investigational obesity portfolio, delivering robust weight loss with no plateau observed at week twenty-eight in vespa three while also maintaining competitive tolerability when switching to a fourfold equivalent monthly dose. We are primed to execute across an expansive phase three program of 3944 targeting potential approval starting in 2028. And we are pursuing differentiated combination approaches with earlier-stage agents that have the potential to deliver greater optionality to address the diverse unmet needs of patients. With that, I'll turn it back to Albert. Albert Bourla: Oh, thank you, Chris. And, I just wanted to say that today's results provide a compelling validation of our unique proprietary ultra-long-acting peptide platform. For the first time, we have shown that GLP-1 receptor agonist peptides can be administered monthly while maintaining the potential for competitive efficacy and safety. We are pleased with this important milestone for the platform that reinforces both the differentiation of our technology and the significant long-term value creation opportunity that it represents. And with that, now I will tu”